A new serological test to detect IgG and IgM antibodies against SARS-CoV-2 has been developed by BIOLAN HEALTH. It is a rapid and easy to use test that, from a drop of capillary blood, will identify people who are or have been infected by the virus that causes COVID-19.

A very distinctive feature of the BIOLAN HEALTH test is that it can detect antibodies directed against the area of SARS-CoV-2 responsible for the entry of the virus into the cell, the Receptor Binding Domain (RBD) of the Spike-1 protein. These RBD-targeting antibodies have the potential to be neutralising against SARS-CoV-2 and may therefore prevent future infections. BIOLAN HEALTH’s new serological test will therefore identify people who have neutralising antibodies to SARS-CoV-2 and who are therefore “potentially” immune.

This means that, in addition to being a useful tool for epidemiological studies to better understand the incidence and spread of the virus, it can also be a very useful tool for evaluating the effectiveness of vaccines.

BIOLAN HEALTH itself will be in charge of its manufacture, for which it has set up a specific production line that will soon be complete with all the necessary equipment, as shown in the following report:
https://www.eitb.eus/es/noticias/sociedad/videos/detalle/7680723/video-la-empresa-biolan-zamudio-desarrolla-test-serologico-rapido/